Skye Bioscience Inc

SKYENASDAQ · USD
1.57USD+1.29 (-7.65%)
122

Skye Bioscience Inc (SKYE) Covered Calls

No qualifying covered call setups were found for SKYE in the prior session.

Read more

Running SKYE covered calls helps you generate consistent income from Skye Bioscience Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Skye Bioscience Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best SKYE covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if SKYE stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling SKYE covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Skye Bioscience Inc covered call is worth writing.

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc.

was founded in 2012 and is headquartered in San Diego, California.

Income-focused investors, long-term SKYE holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling SKYE covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Skye Bioscience Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile92.46% Elevated
  • Market cap (M$)10
  • 52 weeks high-94.39%
  • 52 weeks low0.00%
  • Analyst recommendationBuy
    2.00
  • Target price$7.00
    345.86% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-09
  • P/E
  • Future P/E
  • EPS (ttm)-1.27
  • EPS growth next 5 years0.07%

As of September 17, 2026

No illustrative rows to display.

As of September 17, 2026

Sell covered calls with the data behind you

Find the best SKYE covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial